Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02800148 · ClinicalTrials.gov registry record · Phase 3
Bioequivalence Study of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea on the Face
A Phase 3 study of Rosacea, sponsored by Padagis.
- Completed
- Registry status
- Phase 3
- Development phase
- 667
- Enrollment target
- 1
- Study location
NCT02800148 is a Phase 3 study of Rosacea that has completed, run by Padagis. The registered enrollment target is 667 participants, above the 214-participant average among 23 other Rosacea trials with a reported enrollment target (212% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02800148, a Phase 3 study of Rosacea, has completed, sponsored by Padagis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 667 participants
- Enrollment target
- 1
- Study location
Study Summary
To compare the bioequivalence of Perrigo's azelaic acid foam product to Finacea Foam for the treatment of Inflammatory Lesions of Rosacea
Conditions Studied
Interventions
- DRUG Azelaic acid foam
- DRUG Azelaic acid foam - Placebo
Study Locations (1)
North Carolina
- Dermatology Consultants - High Point
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 667 participants |
| Start Date | 2016-11 |
| Est. Completion | 2017-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02800148
The ClinicalTrials.gov registry entry for NCT02800148 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 667 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 214-participant average among 23 other Rosacea trials with a reported enrollment target (212% higher). The listed sponsor is Padagis, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rosacea appearing as the primary indexed condition, and to 2 interventions - of which Azelaic acid foam is the first listed.
NCT02800148 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT02800148 about?
NCT02800148 is a clinical study titled "Bioequivalence Study of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea on the Face". To compare the bioequivalence of Perrigo's azelaic acid foam product to Finacea Foam for the treatment of Inflammatory Lesions of Rosacea
What is the current status of trial NCT02800148?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 667 participants. The study started on 2016-11. Estimated completion is 2017-10.
What conditions does trial NCT02800148 study?
This clinical trial studies the following conditions: Rosacea.
What interventions are being tested in trial NCT02800148?
The interventions under investigation include: Azelaic acid foam (DRUG), Azelaic acid foam - Placebo (DRUG).
Who is sponsoring clinical trial NCT02800148?
This trial is sponsored by Padagis, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02800148 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea
COMPLETED · Phase 3
-
Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
COMPLETED · Phase 3
-
Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel
COMPLETED · Phase 3
-
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
COMPLETED · Phase 3
-
Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea
RECRUITING · NA
-
Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.